Oxidative stress and level of antioxidant enzymes in drug-naive schizophrenics

Indian Journal of Psychiatry

Volumn 56, Issue 4, 2014, Pages 344-349

  Reyazuddin, Mohammed ^a   Azmi, Suhail A ^a   Islam, Najmul ^a   Rizvi, Abid ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Antioxidative enzymes; drug naive; oxidative stress; schizophrenia

Indexed keywords

GLUTATHIONE PEROXIDASE; MALONALDEHYDE; SUPEROXIDE DISMUTASE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE LEVEL; FEMALE; HUMAN; MALE; MENTAL PATIENT; OUTPATIENT DEPARTMENT; OXIDATIVE STRESS; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA;

EID: 84919789056     PISSN: 00195545     EISSN: 19983794     Source Type: Journal    
DOI: 10.4103/0019-5545.146516     Document Type: Article

References (52)

1. Benjamin JS, Irwin KH, Virginia AS. Schizophrenia. In: Synopsis of Psychiatry. 10 th ed. Lippincott Williams and Wilkins, Wolters Kluwer; Indian edi,1997. p. 467.
2. Sies H. Oxidative stress. Introductory remarks. In: Sies H, editor. Oxidative Stress. London: Academic Press; 1985.
3. Halliwell B, Gutreridge JM. Free Radicals in Biology and Medicine. 2 nd ed. Oxford, UK: Clarendon Press; 1989.
4. Soboll S, Gründel S, Harris J, Kolb-Bachofen V, Ketterer B, Sies H. The content of glutathione and glutathione S-transferases and the glutathione peroxidase activity in rat liver nuclei determined by a non-aqueous technique of cell fractionation. Biochem J 1995;311:889-94.
5. Dumuis A, Sebben M, Haynes L, Pin JP, Bockaert J. NMDA receptors activate the arachidonic acid cascade system in striatal neurons. Nature 1988;336:68-70.
6. Frautschy SA, Baird A, Cole GM. Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc Natl Acad Sci USA 1991;88:8362-6.
7. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it. Ann Neurol 1992;32:804-12.
8. Beal MF. Mitochondria free radicals and neurodegeneration. Curr Opin Neurobiol 1996;6:661-6.
9. Breteler MM, van Amerongen NM, van Swieten JC, Claus JJ, Grobbee DE, van Gijn J, et al. Cognitive correlates of ventricular enlargement and cerebral white matter lesions on magnetic resonance imaging. The Rotterdam Study. Stroke 1994;25:1109-15.
10. Abdalla DS, Monteiro HP, Oliveira JA, Bechara EJ. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin Chem 1986;32:805-7.
11. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002;20:171-5.
12. Bilici M, Efe H, Köroglu MA, Uydu HA, Bekaroglu M, Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: Alterations by antidepressant treatments. J Affect Disord 2001;64:43-51.
13. Fukunaga K, Yoshida M, Nakazono N. A simple, rapid, highly sensitive and reproducible quantification method for plasma malondialdehyde by high-performance liquid chromatography. Biomed Chromatogr 1998;12:300-3.
14. Looney JM, Childs HM. The lactic acid and glutathione content of the blood of schizophrenic patients. J Clin Invest 1934;13:963-8.
15. Altuntas I, Aksoy H, Coskun I, Cayköylü A, Akçay F. Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin Chem Lab Med 2000;38:1277-81.
16. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Description and Diagnostic Guidelines. Geneva: World Health Organization; 1992.
17. Stanley RK, Abraham F, Lewis AO. The positive and negative syndrome scale (panss) for schizophrenia. Schizophr Bull 1987;13:261-76.
18. Andreeva II, Kotemjakin AA, Kishkun AA. A modified thiobarbituric acid test for measuring lipid peroxidation products. Lab Delo 1988;1:41-3.
19. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974;47:469-74.
20. Moin VM. A simple specific method for assays of red cells glutathione peroxidase activity. Lab Delo 1986;12:724-727.
21. Halliwell B. Oxidants and the central nervous system: Some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke? Acta Neurol Scand Suppl 1989;126:23-33.
22. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinines. Mol Pharmacol 1978;14:633-43.
23. McCord JM. Oxygen-derived radicals and reperfusion injury. Ann Intern Med 1987;107:526-45.
24. Singh R, Pathak DN. Lipid peroxidation and glutathione peroxidase, glutathione reductase, superoxide dismutase, catalase and glucose-6-phosphate dehydrogenase activities in FeCl3-induced epileptogenic foci in rat brain. Epilepsia 1990;31:15-26.
25. Vilkov GA, Kiroi RI, Stepnina EG, Smirnova OB, Kovalenko VA, Trapezontseva RA. Lipid peroxidation and microviscosity of erythrocyte membranes in patients with schizophrenia. Zh Nevropatol Psikhiatr Im S S Korsakova 1991;91:45-7.
26. Herken H, Uz E, Ozyurt H, Sögüt S, Virit O, Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001;6:66-73.
27. Akyol O, Herken H, Uz E, Fadillioglu E, Unal S, Sögüt S, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:995-1005.
28. Mahadik SP, Mukherjee S, Scheffer R, Correnti EE, Mahadik JS. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 1998;43:674-9.
29. Zhang XY, Tan YL, Cao LY, Wu GY, Xu Q, Shen Y, et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006;81:291-300.
30. Ben Othmen L, Mechri A, Fendri C, Bost M, Chazot G, Gaha L, et al. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:155-9.
31. Dadheech G, Mishra S, Gautam S, Sharma P. Evaluation of antioxidant deficit in schizophrenia. Indian J Psychiatry 2008;50:16-20.
32. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003;121:109-22.
33. Li HC, Chen QZ, Ma Y, Zhou JF. Imbalanced free radicals and antioxidant defense systems in schizophrenia: A comparative study. J Zhejiang Univ Sci B 2006;7:981-6.
34. Awasthi YC, Beutler E, Srivastava SK. Purification and properties of human erythrocyte glutathione peroxidase. J Biol Chem 1975;250:5144-9.
35. Mukerjee S, Mahadik SP, Scheffer R, Correnti EE, Kelker H. Impaired antioxidative defense at the onset of psychosis. Schizophr Res 1996;19:19-26.
36. Raffa M, Atig F, Mhalla A, Kerkeni A, Mechri A. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry 2011;11:124.
37. Albayrak Y, Ünsal C, Beyazyüz M, Ünal A, Kulolu M. Reduced total antioxidant level and increased oxidative stress in patients with deficit schizophrenia-A preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2013;45:144-9.
38. Fung LW, Zhang Y. A method to evaluate the antioxidant system for radicals in erythrocyte membranes. Free Radical Biol Med 1990;9:289-98.
39. Glen AI, Glen EM, Horrobin DF, Vaddadi KS, Spellman M, Morse-Fisher N, et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: Evidence for two diseases. Schizophr Res 1994;12:53-61.
40. Murphy ME, Sies H. Reversible conversion of nitroxyl anion to nitric oxide by superoxide dismutase. Proc Natl Acad Sci USA 1991;88:10860-4.
41. Heales SJ, Barker JE, Stewart VC, Brand MP, Hargreaves IP, Foppa P, et al. Nitric oxide, energy metabolism and neurological disease. Biochem Soc Trans 1997;25:939-43.
42. Packer MA, Scarlett JL, Martin SW, Murphy MP. Induction of the mitochondrial permeability transition by peroxynitrite. Biochem Soc Trans 1997;25:909-14.
43. Strunecka A, Ripova D. What can the investigation of phosphoinositide signalling system in platelets of schizophrenic patients tell us? Prostaglandins Leukot Essent Fatty Acids 1999;61:1-5.
44. Kyosseva SV, Elbein AD, Griffin WS, Mrak RE, Lyon M, Karson CN. Mitogen-activated protein kinases in schizophrenia. Biol Psychiatry 1999;46:689-96.
45. Mattson MP, Camandola S. NF-kB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 2001;107:247-54.
46. Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, Turankar A. Oxidative damage and schizophrenia: The potential benefit by atypical antipsychotics. Neuropsychobiology 2004;49:205-9.
47. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. The effect of risperidone treatment on superoxide dismutase in schizophrenia. J Clin Psychopharmacol 2003;23:128-31.
48. Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry 2013;74:400-9.
49. Dakhale GN, Khanzode SD, Khanzode SS, Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl) 2005;182:494-8.
50. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 2003a; 62:195-204.
51. Zhang XY, Zhou DF, Zhang PY, Wu GY, Su JM, Cao LY. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2001;62:878-83.
52. Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008;33:2187-99.